Boston Scientific Co. (NYSE:BSX) is Jag Capital Management LLC's 7th Largest Position

Jag Capital Management LLC boosted its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 10.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 301,506 shares of the medical equipment provider's stock after purchasing an additional 27,720 shares during the quarter. Boston Scientific comprises 3.0% of Jag Capital Management LLC's portfolio, making the stock its 7th largest position. Jag Capital Management LLC's holdings in Boston Scientific were worth $25,266,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of BSX. Triad Wealth Partners LLC purchased a new stake in Boston Scientific during the second quarter worth approximately $26,000. Values First Advisors Inc. purchased a new stake in Boston Scientific during the third quarter worth approximately $28,000. E Fund Management Hong Kong Co. Ltd. purchased a new stake in Boston Scientific during the third quarter worth approximately $30,000. Capital Performance Advisors LLP purchased a new stake in Boston Scientific during the third quarter worth approximately $30,000. Finally, First Foundation Advisors purchased a new stake in Boston Scientific during the first quarter worth approximately $25,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

NYSE BSX traded up $0.23 on Monday, reaching $88.48. The company's stock had a trading volume of 3,945,615 shares, compared to its average volume of 6,082,172. Boston Scientific Co. has a twelve month low of $52.99 and a twelve month high of $88.94. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.14 and a current ratio of 1.48. The stock has a market cap of $130.40 billion, a PE ratio of 73.17, a PEG ratio of 2.60 and a beta of 0.79. The firm's 50 day moving average is $84.61 and its two-hundred day moving average is $79.05.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, beating analysts' consensus estimates of $0.59 by $0.04. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. The company had revenue of $4.21 billion during the quarter, compared to the consensus estimate of $4.04 billion. During the same period in the prior year, the company earned $0.50 EPS. Boston Scientific's revenue was up 19.3% on a year-over-year basis. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.46 EPS for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on BSX. Stifel Nicolaus boosted their price objective on shares of Boston Scientific from $85.00 to $100.00 and gave the stock a "buy" rating in a research note on Friday, October 18th. Sanford C. Bernstein boosted their target price on shares of Boston Scientific from $92.00 to $100.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Bank of America boosted their target price on shares of Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Tuesday, October 22nd. StockNews.com cut shares of Boston Scientific from a "buy" rating to a "hold" rating in a research report on Monday, November 4th. Finally, Mizuho boosted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an "outperform" rating in a research report on Thursday, October 24th. Four research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $93.39.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 162,777 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now directly owns 1,572,096 shares of the company's stock, valued at approximately $133,046,484.48. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 132,527 shares of the company's stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $85.00, for a total transaction of $11,264,795.00. Following the completion of the sale, the executive vice president now directly owns 160,467 shares of the company's stock, valued at approximately $13,639,695. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 162,777 shares of the stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now directly owns 1,572,096 shares of the company's stock, valued at $133,046,484.48. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 309,270 shares of company stock valued at $26,196,718. 0.50% of the stock is currently owned by corporate insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.